Substantial numbers of human fetuses and infants are exposed to therapeutic drugs (e.g., drugs that stop the mother-to-child transmission of human immunodeficiency virus (HIV) 1 and endocrinedisrupting chemicals 2 . Perinatal exposure to these chemicals can cause genotoxic or epigenetic changes, which may increase the risk of developing cancer or other diseases later in life 3, 4 . As a result, animal testing models that can evaluate the long-term consequences of exposure to these chemicals during gestation and early postnatal life are becoming increasingly important. In order to produce results that can be used by regulatory authorities to formally assess the risk such chemicals pose to humans, toxicity studies should be done under conditions that meet Good Laboratory Practice standards. These standards help to ensure the accuracy, reproducibility, integrity and quality of study results.
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Automated gavage pumps can provide accurate drug doses for adult rodents, but such systems do not accurately dispense the small volumes typically administered to neonatal mice. To help improve dose accuracy, especially for small volumes, we inserted Teflon tubing into the needle cup of an automated pipetting system to reduce the amount of dead space in the needle cup. This minimized the dilution of the test substance with vehicle solution that had been used to prime the system and allowed us to deliver more precise drug doses to both adult and neonatal mice.
We used this modified pipetting system for a series of studies that mimicked the recommended dosing regimens of pregnant women and infants who take combination antiretroviral drugs to treat or prevent HIV infections 1, 5 . These studies required that neonatal and adult mice be dosed with these drugs (via oral gavage) as either single preparations (soluble solutions or colloidal suspensions) or in combination (colloidal suspensions). We adapted the automated pipetting system to deliver discrete, individual doses ranging from 5 µl for neonatal mice to 400 µl for adults. We used nucleoside reverse transcriptase inhibitors (zidovudine, AZT, and lamivudine, 3TC) and a nonnucleoside reverse transcriptase inhibitor (nevirapine, NVP) to validate this modified pipetting system, but other compounds could be administered to mice or rats using this system.
To ensure that our results could be compared with results from other oral gavage toxicity studies, we
To assess a drug's toxic or carcinogenic effects on neonatal and adult mice and rats, researchers often carry out oral gavage studies. Whether dosed singly or in various combinations, provided as soluble solutions or as colloidal suspensions, the drug must be delivered in accurate and precise doses. For studies that require newborn mice to receive multiple daily doses, delicately handling neonates to increase their chances of surviving is just as critical as the ability to accurately dose small volumes. To help ensure accurate and precise delivery of drug doses ranging from 5 µl for neonatal mice to 400 µl for adults, the authors adapted an automated pipetting system. By slightly modifying standard gavage needles, the authors delivered, on average, 98-99% of targeted dose volumes to neonatal mice.
had to accurately dose the rodents and follow strictly standardized handling and gavaging procedures. These standard procedures prevented the rodents from being harmed by the procedures. Since these studies required dispensing up to two drug aliquots per d to neonatal rodents that were as young as postnatal day (PND) 1, minimizing handling and dosing stress to rodents was just as important as rapidly dosing small volumes. Some of the drug preparations that we were administering had limited solubility and flow properties. Therefore, we used a hand-held dispensing probe to aspirate each dose from the dose vial before gavage (individually aspirated gavage dosing) instead of continuously pumping doses from a reservoir (serial dosing).
METHODS

Animals
Mice that were haploinsufficient with respect to Trp53, the gene encoding p53, were bred at the National Center for Toxicological Research (NCTR) under an academic license from Taconic Laboratory Animals and Services, Inc. (Germantown, NY). These mice were derived from C3H/HeN wild-type females and B6.129-Trp53 tm1Brd N12 (homozygous Trp53-null) males. We cared for the mice in accordance with the requirements of the Guide for the Care and Use of Laboratory Animals 6 . These studies were approved by the IACUC at NCTR. For these studies, we dosed pregnant dams (gestational days 12 through 18) by gavage with either AZT or NVP alone or a mixture of AZT, 3TC and NVP (data not shown). The F 1 pups were dosed from PND 1-28 with a mixture of AZT, 3TC and NVP (data not shown) or with AZT or NVP alone. To maintain equivalent serum concentrations, we administered lower doses and dose volumes to younger pups than to older pups and adults. From PND 1-10, pups received half the daily adult dose. After PND 11, pups received the same dose and volume as adults.
Chemicals and preparation of doses
We stored AZT, 3TC and NVP (Bryon Chemical Company, Inc., Long Island City, NY) in amber jars (Fisher Scientific, Inc., Pittsburgh, PA) at room temperature. We prepared doses in a dosing vehicle consisting of 0.2% methylcellulose and 0.1% polysorbate 80 (Sigma-Aldrich Corp., St. Louis, MO) in water. Both AZT and 3TC were soluble in the dosing vehicle. NVP was not soluble in the dosing vehicle and was delivered as a colloidal suspension using our modified system. We used sonication to suspend all suspension mixtures and kept the mixtures in septum-sealed vials that were constantly stirred.
When administered alone, the maximum concentration of AZT solution was 24 mg AZT per ml dosing solution, which, when administered at 10 ml solution per kg body weight, provided adult mice with a dose of 240 mg AZT per kg body weight. The maximum concentration of NVP suspension when used alone was 8.4 mg NVP per ml dosing solution, which, when administered at 10 ml suspension mixture per kg body weight, provided adult mice with a dose of 84 mg NVP per kg body weight. Mice that received these doses of NVP were dosed twice per d, resulting in a daily dosage of 168 mg NVP per kg body weight.
We prepared combination doses of AZT, 3TC and NVP in the same mixture preparation. The mixture concentrations were as low as 4.0 mg AZT, 2.5 mg 3TC and 2.8 mg NVP per ml dosing vehicle. When administered at 10 ml mixture per kg body weight, this mixture provided adult mice with a dose of 40 mg AZT, 25 mg 3TC and 28 mg NVP per kg body weight. Mice were dosed twice per d, resulting in a daily dosage of 80 mg AZT, 50 mg 3TC and 56 mg NVP per kg body weight. The mixture concentrations were as high as 20 mg AZT, 12.5 mg 3TC and 14.0 mg NVP per ml dosing vehicle. When administered at 3 ml per kg body weight, this mixture provided neonatal mice with a dose of 60 mg AZT, 37.5 mg 3TC and 42 mg NVP per kg body weight. These neonatal mice were also dosed twice per d.
Dose analysis
We calculated the amount of adult and pup doses for dose accuracy analysis based on average weights of adult mice (30 g) and pups (2 g; determined from weighing litters of six pups as a group). To determine dose mixture concentrations and the accuracy of dispensed doses, we used high-performance liquid chromatography (HPLC) analysis. For all of these measurements, we used a Millennium HPLC System (Waters Corp., Milford, MA), consisting of a Model 600 pump, 717plus Autosampler, Nova-Pak C18 analytical column cartridge (60 Å pore size, 4 µm particle size, 3.9 mm × 150 mm) and a 996 photodiode array detector (we monitored the 254 nm wavelength). The drugs were eluted at a flow rate of 1 ml per min using a solution consisting of methanol and water (0.005 M sodium phosphate monobasic, 0.003 M sodium pentanesulfonic acid, pH 2.5; linear gradient ranging from 5:95 to 90:10 v:v of methanol:water).
While modifying the pipetting system, we used malachite green dye (Sigma-Aldrich, St. Louis, MO) to test aspirated volume recovery. We dissolved the dye in the dosing vehicle (concentrations of 6 or 0.6 mM) and spectrophotometrically (618 nm; Cary 100 Bio UV/Visible spectrophotometer, Varian, Inc., Palo Alto, CA) measured the difference between aspirated and dispensed solutions.
Initial setup and modifications to the system Initial setup. The gavaging system (Fig. 1) that we used consists of a high-precision, single-syringe dispenser (automatic pipettor; Microlab 500 Series, Hamilton Company, Reno, NV), 18-gauge pipette tubing (approximately 900 cm long; Hamilton Company) and a syringe (1.0 ml for adult mice; 0.5 ml for pups; Hamilton Company). The dispenser system includes a push-button dispensing probe (part # 35899; Hamilton Company) with a Luer lock connector. We attached the probe to a stainless steel mouse gavage needle (1.5-in, 22-gauge, 1.25-mm ball needle for adults and 1-in, 24-gauge, 1.25-mm ball needle for pups; Harvard Apparatus, Holliston, MA). We primed the system with a dosing vehicle solution.
Before each dosing, we washed out the needle by aspirating the dispensing system with 200 µl of the solution to be dosed. We dispensed the doses at a speed of 167 µl per s for adults and 83 µl per s for pups, which corresponds to a setting of 6 s per syringe stroke with a 1 ml or 0.5 ml syringe, respectively.
To keep the colloidal suspensions uniformly dispersed, the suspensions were continuously stirred in the vials. We dispensed each dose by aspirating the volume directly from the dose-containing vial through the probe and gavage needle, rather than pumping each dose from the syringe. For adults, we individually aspirated each dose before dispensing it. For pups, we aspirated enough volume to dose a litter of six pups (plus one extra dose) and then dispensed these doses separately. A small slit was cut in each vial's septum before use to avoid damage to the gavage needle.
Modifications. The gavage needle is designed to fit onto the probe tip so that the walls of each form a seal when the outer rim of the needle cup locks onto the Luer lock connecter (Fig. 2) . The cup at the end of the gavage needle is 4 mm in diameter at the top, has a cup depth of 11.2 mm and is tapered. The Luer lock connector tip is approximately 3.8 mm in diameter and also has a slight taper. When the gavage needle is placed inside the probe tip, there is a dead space (approximately 65 µl) at the base of the cup (Fig. 2) . This dead space could have been causing dilution to occur during dose aspiration. To decrease the dead space volume, we inserted Teflon tubing and a nitrile rubber O-ring (which secured the tubing) into the needle cup.
First, we substituted doses with solutions of malachite green dye dissolved in the dosing vehicle. We then spectrophotometrically measured dye concentrations and calculated potential dose dilution due to the dead space. We also weighed dispensed aliquots to determine the accuracy of volumes administered from the needle. Using this method, we determined the Teflon tubing dimensions and O-ring size needed to reduce dead space in the cups of the different gavage needles (data not shown). We inserted a piece of Teflon tubing (3.1 mm long; 3.2 mm outer diameter; and 0.8 mm inner diameter, 20-gauge; Bio-Rad Laboratories, Hercules, CA) and a nitrile rubber O-ring (4 mm outer diameter; 2 mm inner diameter; BN70, O-rings Inc., Los Angeles, CA) in the needle cup (Fig. 2) . We used the same size of tubing to fit both the 22-gauge and 24-gauge needles. For the adult dosing system, we replaced the pipette tubing that supplies the pipettor with longer pipette tubing (1.25 m long; 18-gauge) to prevent the aspirated dose from reaching the pump's valve and syringe.
Dosing and litter survival
We used the modified pipetting system to administer either AZT or NVP to mouse pups from PND 1-28. Mice were weighed each day, prior to dosing, to determine dose volume. Adult mice and pups (PND 11-28) were weighed individually; litters (PND 1-10) were weighed as groups. Some of the pups received one daily dose of AZT as a soluble preparation (24 mg AZT per ml dosing vehicle; 5 ml per kg body weight from PND 1-10 and at 10 ml per kg body weight from PND 11-28). Other pups received AZT as a soluble preparation twice per d at 3 ml per kg body weight from PND 1-10 (20 mg per ml dosing vehicle) and then at 10 ml per kg body weight from PND 11-28 (12 mg per ml dosing vehicle). The pups receiving semi-colloidal suspensions of NVP in dosing vehicle received doses twice per d at 3 ml per kg body weight from PND 1-10 (3.5 mg per ml PND 1-3; 14 mg per ml PND 4-10) and then at 10 ml per kg body weight from PND 11-28 (8.4 mg per ml).
Interfacing with the animal unit computer system
We further modified the automatic pipettor by linking the pipettor function signals to a dosing protocol software program. We developed this validated integration software to replace hardware control functions. The software automated the identification of animals and doses, weighing of animals and dose administration, thus bypassing manual operations on the pipettor keypad.
To enhance pipettor function, we used a Microsoft ActiveX control (MSComm; a small computer program) to send and receive commands and data to and from the Hamilton unit via a bidirectional serial port. To ensure precisely timed delays between receipt and execution of a command by the program, we wrote a function in Visual Basic that programmed the software to use the Windows operating system timing functions. After a command is sent, this delay function causes the MSComm program to 'sleep' for a specified number of milliseconds before the program carries out the command.
The original pipetting system could not send signals to an external controller. To allow for bidirectional communication between the pipettor system and the external controller, we designed an external interface circuit, which we housed inside a black box (Fig. 1) . The circuit consists of a microcontroller chip, a NAND-gate chip, a TTL RS232 converter, RS-232-IN connectors, a reset button and a two-pole mini-phone connector to connect the contact closure device. When activated, the microcontroller chip generates the ASCII code 2A (an asterisk character). Applied in series with the RS232 line, the circuit allows normal RS232 communication and inserts the asterisk character to alert the computer when the contact closure is activated.
The NCTR Multi-Generation Support System (MGSS) database retrieved data from this complete interactive system (Fig. 1) on a daily basis. The MGSS certified reporting system, which provides animal data, daily technician observations, breeding records and other information required for a protocol, is compliant with the Good Laboratory Practices requirement for animal experimentation at NCTR.
rESuLTS
Dose analysis for unmodified and modified needles
To determine the accuracy of each dispensed dose, we dispensed doses through appropriately sized gavage needles into volumetric flasks. Initial chemical analyses of aliquots dispensed with the pipettor showed that the dose dispensed with unmodified adult and pup gavage needles ranged from 80% to 91% of the target dose ( Table 1) . This occurred because the dose volume and residual dosing vehicle (the latter used to prime the system and purge the system between doses) were mixing and causing dose dilution within the gavage needle cup.
Adapting the needle cup with the Teflon tubing and rubber O-ring lowered dose dilution, thereby delivering AZT doses that were closer to target AZT doses ( Table 1) . Modified needles allowed accurate, reproducible dose delivery of volumes ranging from 60 µl to 400 µl. Chemical analyses of dose aliquots showed that the modified needle cup delivered an average of 95% of the targeted dose for adult doses (200-400 µl) and an average of 99% of the targeted dose for litter doses (60 µl). The results show that neonates usually received more than 95% of the targeted dose. Dosing a combination-drug suspension with modified needles delivered an average 96% and 99% (adult doses at 300 µl and litter doses at 30 µl, respectively) of the targeted dose across all of the drugs tested ( Table 2 ). The differences in the percentage recovery of AZT and 3TC (in solution) and NVP (in suspension) were small ( Table 2) .
Pup survival
We dosed the newborn mouse pups (Fig. 3) either once per d (with a volume of 5 ml per kg body weight), or twice per d (approximately 6 h apart, with a volume of 3 ml per kg body weight per administration). From PND 1 to PND 28, 100% of the control, untreated pups survived ( Table 3) . More than 97% of pups that were initially dosed once per d with a soluble solution of AZT alone survived from PND 1 to PND 10, a time likely to cause greatest trauma or stress to the neonate and its mother ( Table 3) . These pups had a similar survival percentage (97%) during the PND 11-28 interval ( Table 3) . Pups dosed twice per d with either a soluble solution (AZT) or a colloidal suspension (NVP in dosing vehicle) also had a similar survival rate (96%) from PND 1 to PND 28.
DISCuSSION
Our results show that the modified needles accurately delivered doses (ranging from 5 µl to 400 µl) of single solutions and mixed solutions to adult and neonatal mice (Tables 1 and 2) . Additionally, for the combination doses, percentages of AZT and 3TC (in solution) and NVP (in suspension) delivered by the modified system did not differ substantially. Thus, by making minor modifications to the dosing system, we were able to deliver more accurate doses of both solutions and suspensions. This modification was particularly helpful for low-volume dose delivery to neonatal mice.
While pup losses were minimal, dosed pups had a lower survival rate than did their nondosed counterparts; their fragility during handling was a contributing factor. Deaths tended to be clustered in individual litters, suggesting that maternal behavior might have influenced pup survival. Increased handling and gavaging of the neonatal pups during the twice-daily regimen probably contributed to the relatively higher mortality in this group than in other groups ( Table 3) . Drug toxicity, though potentially a factor, did not substantially increase mortality once the pups were older than PND 10. At ages greater than PND 10, pups had achieved a level of tolerance for both the stressors of gavage dosing and drug combinations. Pup survival 
